Dynasty Wealth Management LLC Takes $445,000 Position in Amgen Inc. $AMGN

Dynasty Wealth Management LLC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,576 shares of the medical research company’s stock, valued at approximately $445,000.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Amgen by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock worth $14,996,807,000 after acquiring an additional 841,117 shares in the last quarter. State Street Corp grew its stake in Amgen by 0.6% in the second quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock valued at $8,196,775,000 after purchasing an additional 177,035 shares during the last quarter. Geode Capital Management LLC raised its holdings in Amgen by 2.3% in the second quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock worth $3,619,489,000 after purchasing an additional 291,271 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Amgen by 5.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after buying an additional 687,735 shares in the last quarter. Finally, Laurel Wealth Advisors LLC grew its position in shares of Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after buying an additional 6,676,575 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 10,908 shares of company stock valued at $3,674,966. 0.69% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on AMGN shares. Scotiabank assumed coverage on shares of Amgen in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 target price for the company. HSBC reissued a “buy” rating and issued a $425.00 price objective on shares of Amgen in a research report on Wednesday, December 10th. Daiwa Capital Markets upped their target price on Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. Piper Sandler raised their price target on Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Finally, Argus upped their price objective on shares of Amgen from $310.00 to $360.00 and gave the company a “buy” rating in a report on Tuesday, December 30th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $339.24.

Amgen Stock Up 0.2%

Shares of AMGN stock opened at $331.00 on Wednesday. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $346.38. The firm has a market capitalization of $178.24 billion, a PE ratio of 25.58, a P/E/G ratio of 2.94 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The stock’s 50-day simple moving average is $331.55 and its 200-day simple moving average is $306.64.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same quarter in the prior year, the firm earned $5.58 earnings per share. Amgen’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Friday, February 13th. Amgen’s payout ratio is presently 77.90%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.